YS Biopharma Co. Ltd. has received clinical trial approval by the Philippine Food and Drug Administration to begin a phase I trial of its YS-HBV-002 immunotherapeutic vaccine, designed to treat chronic hepatitis B virus (HBV) infection. The trial will begin in the Philippines in June.
Dysfunction of the complement system plays an important role in the pathogenesis of renal diseases. Complement inhibitors, such as C5 inhibitors, have shown efficacy in clinical trials, but may not be sufficient to block disease progression as monotherapy.
CD276-based immunotherapy strategies have demonstrated potent antitumor activity and feasibility for clinical application in solid tumors. In urothelial bladder cancer, CD276 is also aberrantly expressed. However, the exact role of CD276 in bladder cancer tumorigenesis and its potential clinical significance remain unexplored.
Pfizer Inc. has described serine/threonine-protein kinase (SIK) inhibitors reported to be useful for the treatment of arthritis, cancer, osteoporosis, atherosclerosis, inflammatory bowel disease, autoimmune diseases, inflammatory disorders and pain.
Shanghai Apeiron Biotechnology Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Origenis GmbH has identified cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, obesity, diabetes, viral infections, cardiovascular disorders and inflammatory disorders.
Eli Lilly & Co. has synthesized glucocorticoid receptor (GR) agonists reported to be useful for the treatment of atopic dermatitis and rheumatoid arthritis.
Wista Laboratories Ltd. has disclosed thiazole-containing compounds acting as microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of corticobasal syndrome, Alzheimer’s disease, Down syndrome and more.
Despite GTPase KRAS being the most common mutated oncogene in human cancers, there is still an unmet medical need for treating KRAS G12C-mutated cancers.
RSS
